NCT04828434

Brief Summary

Due to COVID-19, the routine treatment for dementia, Cognitive Stimulation Therapy (CST), is currently suspended in multiple countries. Access to treatment is, therefore, paramount. The investigators seek to bridge the current treatment gap with a virtual and individual form of CST, called Virtual Individual Cognitive Stimulation Therapy (V-iCST). This psychosocial intervention was adapted from the key principles of CST and developed within the Medical Research Council (MRC) framework for complex interventions. The investigators aim to evaluate the feasibility and acceptability of V-iCST in a Randomized Controlled Trial. This is a feasibility randomized controlled trial (RCT) for Virtual Individual Cognitive Stimulation Therapy (V-iCST), an evidence-based teletherapy for people with mild to moderate dementia. This psychosocial intervention is adapted from a routine and established dementia treatment, Cognitive Stimulation Therapy, and developed within the Medical Research Council (MRC) framework for complex interventions.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
34

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 23, 2021

Completed
9 days until next milestone

Study Start

First participant enrolled

April 1, 2021

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 2, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2023

Completed
2.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2025

Completed
Last Updated

March 25, 2022

Status Verified

March 1, 2022

Enrollment Period

2 years

First QC Date

March 23, 2021

Last Update Submit

March 24, 2022

Conditions

Keywords

DementiaRandomized Controlled TrialCognitive StimulationMild to Moderate DementiaTeletherapyPsychosocial Interventions

Outcome Measures

Primary Outcomes (5)

  • Recruitment (feasibility of V-iCST)

    Feasibility of recruitment by successful recruitment of the target sample of 32 in a 24-month period.

    Descriptive data will be collected during the study and analysed post-intervention; through study completion, 2 years

  • Retention rate (feasibility of V-iCST)

    Retention rate of at least 75% of participants at 9-week follow-up.

    Descriptive data will be collected during the study and analyzed post-intervention; at 9-week follow-up

  • Attendance and retention rate (acceptability of V-iCST)

    Overall attendance and retention rates among the participants (60%) at 9-week follow-up.

    Descriptive data will be collected during the study and analyzed post-intervention; at 9-week follow-up

  • Negative of adverse events (acceptability of V-iCST)

    Any negative or adverse events related to the intervention

    Descriptive data will be collected during the study and analyzed post-intervention; through study completion, 2 years

  • Fidelity (acceptability of V-iCST)

    Fidelity will also be assessed to ensure that facilitators adhered to the protocol. Fidelity will be evaluated by a) facilitators' completion of the fidelity checklist following each session; b) vide recordings of all sessions and an independent researcher rating fidelity with a random 10% of the recordings.

    Descriptive data will be collected during the study and analyzed post-intervention; through study completion, 2 years

Secondary Outcomes (6)

  • Change in cognitive function

    Pre-test (baseline: week 0) and post test (week 9)

  • Change in cognitive function

    Pre-test (baseline: week 0) and post test (week 9)

  • Change in quality of life

    Pre-test (baseline: week 0) and post test (week 9)

  • Change in mood

    Pre-test (baseline: week 0) and post test (week 9)

  • Change in communication

    Pre-test (baseline: week 0) and post test (week 9)

  • +1 more secondary outcomes

Study Arms (2)

Virtual Individual Cognitive Stimulation Therapy

EXPERIMENTAL

Virtual Cognitive Stimulation Therapy (V-iCST), a psychosocial intervention, is a modified version of CST for people with mild to moderate dementia. Like the original CST, each of the 14 sessions will begin with a "warm-up activity," which includes an orientation task and discussion of current affairs, followed by a main activity. V-iCST will be prescribed to participants twice a week, for 7 weeks and each session is approx. 45 minutes. The intervention will be delivered by trained professionals, such as research staff, psychologists, and trainee clinical psychologists. All facilitators will have experience in dementia care and will have completed the CST training.

Other: Virtual Individual Cognitive Simulation Therapy

Treatment as usual

NO INTERVENTION

Standard care.

Interventions

Virtual Individual Cognitive Stimulation Therapy (V-iCST) is an individual and virtual adaptation of Cognitive Stimulation Therapy (CST), a routine psychosocial treatment for people with mild to moderate dementia in the UK.

Virtual Individual Cognitive Stimulation Therapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of dementia, according to the DSM-IV
  • MoCA - BLIND ≥ 2
  • Age ≥ 18
  • Ability to communicate in English
  • Ability to complete outcome measures
  • Capacity to consent
  • Consent to video-conferencing
  • Access to video-conferencing

You may not qualify if:

  • \) Illness and disability that affects participation (as deemed by researcher)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UCL

London, WC1E 6BT, United Kingdom

Location

Related Publications (6)

  • Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality of life in older adults with cognitive impairment. Psychosom Med. 2002 May-Jun;64(3):510-9. doi: 10.1097/00006842-200205000-00016.

    PMID: 12021425BACKGROUND
  • Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984 Nov;141(11):1356-64. doi: 10.1176/ajp.141.11.1356.

    PMID: 6496779BACKGROUND
  • Kinney JM, Rentz CA. Observed well-being among individuals with dementia: Memories in the Making, an art program, versus other structured activity. Am J Alzheimers Dis Other Demen. 2005 Jul-Aug;20(4):220-7. doi: 10.1177/153331750502000406.

    PMID: 16136845BACKGROUND
  • Holden UP, Woods RT. Positive approaches to dementia care. Edinburgh: Churchill Livingstone, 1995.

    BACKGROUND
  • Yesavage JA, Sheikh JI. Geriatric Depression Scale (GDS) Recent evidence and development of shorter version. Clin Gerontol. 1986;5(1-2):165-73.

    BACKGROUND
  • Wittich W, Phillips N, Nasreddine ZS, Chertkow H. Sensitivity and Specificity of the Montreal Cognitive Assessment Modified for Individuals who are Visually Impaired. Journal of Visual Impairment & Blindness. 2010;104(6):360-368.

    BACKGROUND

MeSH Terms

Conditions

DementiaDementia, VascularMixed DementiasLewy Body DiseaseLymphoma, FollicularAlzheimer DiseaseDementia, Multi-InfarctPick Disease of the Brain

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurocognitive DisordersMental DisordersCerebrovascular DisordersIntracranial ArteriosclerosisIntracranial Arterial DiseasesLeukoencephalopathiesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesParkinsonian DisordersBasal Ganglia DiseasesMovement DisordersSynucleinopathiesNeurodegenerative DiseasesLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesTauopathiesCerebral InfarctionBrain InfarctionBrain IschemiaStrokeInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosisFrontotemporal DementiaFrontotemporal Lobar Degeneration

Study Officials

  • Aimee Spector, PhD, DClinPsy

    UCL

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Single-blind. The assessor will be blinded. Due to the nature of the intervention, the facilitator, and participants cannot be blinded.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 23, 2021

First Posted

April 2, 2021

Study Start

April 1, 2021

Primary Completion

April 1, 2023

Study Completion

September 1, 2025

Last Updated

March 25, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will share

Study results will be published in peer-reviewed journals, doctoral theses and presented at conferences, and disseminated to the public through information sheets. Participants who indicate their interest in receiving further information regarding dissemination will be sent a letter with the main findings of the study upon completion.

Time Frame
Upon study completion.
Access Criteria
Email authors.

Available IPD Datasets

International Cognitive Stimulation Therapy Centre Website Access

Locations